Literature DB >> 26932960

A Charge Comparison of Audiometric Testing in the Pediatric Population.

Samuel J Trosman1, Katie Geelan-Hansen1, Samantha Anne2.   

Abstract

OBJECTIVE: To determine the charges associated with performing combined tympanometry and otoacoustic emissions vs a comprehensive audiogram in the pediatric population and to analyze its implications for future practice. STUDY
DESIGN: Retrospective charge analysis.
SETTING: Tertiary care academic center. SUBJECTS AND METHODS: Analysis was performed on 538 pediatric patients who underwent audiometric hearing testing from May through October 2014.
RESULTS: In total, 401 patients had combined tympanometry and otoacoustic emissions testing and 91 patients underwent a comprehensive audiogram, while 46 patients underwent all 3 tests. The technical and professional charges for combined tympanometry and otoacoustic emissions were $139 and $116, respectively, with an overall charge of $255. The technical and professional charges for an audiogram were $124 and $198, respectively, with an overall charge of $322.
CONCLUSION: Objective testing with a combination of tympanometry and otoacoustic emissions charges insurers $67 less than an audiogram. Given the questionable reliability of behavioral audiometry in very young children, this is a factor to consider when choosing the appropriate test. With a large number of pediatric auditory hearing tests performed each year, the cost savings within the health care system could be substantial. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2016.

Entities:  

Keywords:  audiometry; charge analysis; hearing loss; otoacoustic emissions; tympanometry

Mesh:

Year:  2016        PMID: 26932960     DOI: 10.1177/0194599816635144

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  1 in total

1.  Long-term vancomycin use had low risk of ototoxicity.

Authors:  Clayton Humphrey; Michael P Veve; Brian Walker; Mahmoud A Shorman
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.